APSR2026-735

 
Late-Breaking
Submitted
Poster Presentation
 
AP14-070
P89
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1221182-46904-APSR-735_440001.pdf
Format: PDF Only
08. Lung Cancer
1

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Adhitri Anggoro * Universitas Airlangga Pulmonology and Respiratory Medicine Department of Medical Faculty Surabaya Indonesia Mitra Keluarga Waru Hospital Pulmonology Divsion Sidoarjo Indonesia
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
Adhitri
Anggoro
adhitri.anggoro@fk.unair.ac.id
+628176648493
31-40
Indonesia
Case Report
Stable disease with platinum-based chemotherapy plus serplulimab in EGFR wild-type stage IV lung adenocarcinoma: a case report
Maximum 25 words
Abstract Content
 
 
 
 
Lung cancer remains the leading cause of cancer mortality, with most non-small cell lung cancer (NSCLC) cases diagnosed at an advanced stage and lacking actionable driver mutations.1 Immune checkpoint inhibitors (ICIs), particularly PD-1/PD-L1 inhibitors, combined with platinum-based chemotherapy have become the standard first-line treatment, improving survival irrespective of PD-L1 expression.2,3 However, responses remain heterogeneous, and optimal use of newer agents requires further clarification. Serplulimab, a novel anti-PD-1 antibody, has demonstrated promising efficacy in combination with chemotherapy in advanced NSCLC.4,5 Nevertheless, its role in lung adenocarcinoma remains underreported, with most evidence derived from mixed NSCLC populations.
A 63-year-old woman presented with progressive dyspnea, cough, chest pain, weight loss, and massive right pleural effusion. Cytology confirmed metastatic adenocarcinoma. Molecular testing showed EGFR wild-type and no actionable mutations. CT imaging revealed T4N2M1b disease. The patient received pemetrexed–carboplatin plus serplulimab every three weeks for six cycles. Treatment resulted in significant symptomatic improvement, resolution of recurrent pleural effusion, and stable disease by RECIST. Quality of life improved substantially.
This case demonstrates clinically meaningful disease stabilization in advanced lung adenocarcinoma treated with serplulimab-based immunochemotherapy. Although objective tumor response is often prioritized, durable disease control is a critical endpoint in stage IV NSCLC, particularly in symptomatic patients with malignant pleural effusion. In this patient, stabilization was accompanied by significant symptom relief and improved quality of life, underscoring the clinical relevance of non-progressive disease. The absence of progression supports the immunomodulatory mechanism of PD-1 inhibition, where sustained antitumor immune activity may occur without substantial tumor shrinkage. The combination with platinum–pemetrexed chemotherapy likely provides a synergistic effect by enhancing tumor antigen release and immune recognition. Given that evidence for serplulimab is largely derived from heterogeneous NSCLC populations, this case highlights its potential role in lung adenocarcinoma and underscores the need for histology-specific studies to better define its efficacy.
 
 
Yes
Yes
https://storage.unitedwebnetwork.com/files/1285/1221182-37089-Table1_381252.png
JPG or JPEG or PNG format ONLY
Lung adenocarcinoma; Non-small cell lung cancer; Serplulimab; PD-1 inhibitor; Immunochemotherapy; Platinum-based chemotherapy; EGFR wild-type; Stable disease
maximum 3 keywords and no abbreviations, separated by commas
The authors declare that there are no conflicts of interest related to this work. No specific funding was received for this study. Written informed consent was obtained from the patient for publication of this case report and accompanying images.
307